Biotech Values

[poorgradstudent]

Re: MDVN

What is somewhat surprising to me is how short the median treatment duration on Xtandi was in TERRAIN, only 11.8 months, compared to 16.6 months in PREVAIL. Compared to mPFS of 15.7 months, it seems patients stopped taking the drug much earlier in TERRAIN. Is this due to discontinuation from AEs? This might put a big question mark on whether there will be any benefit to the company by pushing the drug into earlier usage in the future.

I've been thinking about this as well. I don't know if docs give different considerations for discontinuations from AE in this setting versus the castration-resistant setting in PREVAIL.

But it blew casodex out of the water, so then do we ignore that simply because median PFS was shorter in TERRAIN than PREVAIL? Or perhaps there is a sequence-of-treatment consideration now.

I'm with you that it will be meaningful to know the reasons for discontinuation in this trial.